Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Risk OfficerBuy
Generated at:2026-03-05 05:44:21
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-03-04
  • Fundamentals Outweigh Technical Weakness: The Aggressive Analyst correctly notes that Eli Lilly's weak technicals are overshadowed by its strong fundamentals, with 94.9% net income growth and pipeline diversification justifying the high P/E, while the Conservative focus on technical downtrends ignores historical opportunities in high-growth stock pullbacks.
  • Oversold Condition as Opportunity: Technical indicators show oversold levels (RSI: 44.09/38.00, Williams %R: -86.49) similar to December 2025's successful 12.97% gain, validating the original plan's stop-loss at $950 despite Neutral's overly cautious phased approach.
  • Counterarguments Mitigated: Conservative concerns about volatility and stop-loss risks are addressed through refined stop-loss at $950 (-5.3%), improved from past mistakes with -7.5% stops, and valuation concerns are growth-driven as confirmed by 2025-12-08 trade success.
  • Learning from History Supports Decisive Action: Past trades highlight LLY's 50% stop-loss trigger rate but reward oversold entries, with worst-case MAE (-10.50%) justifying $950 stop, favoring buy-with-stop over hold/sell as hesitation caused November 2025 losses.
Aggressive views
  • 94.9% YoY net income growth and 44.7% revenue growth justify premium valuation
  • Current pullback (-9.4% from highs) is a healthy consolidation offering high-reward entry
  • Oversold technical conditions (RSI: 44.09/38.00, Williams %R: -86.49) support entry
  • Strong pipeline catalysts (EMA approval for Olumiant, oral GLP-1 progress)
  • $950 stop-loss is adequate given growth trajectory and underpenetrated GLP-1 market
Neutral views
  • Fundamentals are strong but technical risks are real
  • Phased approach: initial buy near $1,000, add positions at $950–$970
  • Wider stop-loss at $920–$930 to account for volatility
  • Balances upside potential with risk management
  • Macro factors (FDA actions, competitive dynamics) could impact performance
Conservative views
  • Technical indicators signal downtrend with price breaching all moving averages
  • High volatility (ATR: $34.55) and unsustainable P/E of 91.43
  • 50% stop-loss trigger rate and -10.50% MAE indicate high risk
  • $950 stop-loss is too tight for LLY's volatility
  • Recommend waiting for technical confirmation of reversal before entering

Decision

Decision summary

After evaluating the debate among the three risk analysts, the strongest points from each perspective are:

  • Aggressive Analyst: Eli Lilly’s exceptional fundamental strength—94.9% YoY net income growth, 44.7% revenue growth, and robust profitability metrics (ROE: 290.87%, ROA: 52.44%)—justifies its premium valuation. The current pullback (-9.4% from highs) is a healthy consolidation offering a high-reward entry opportunity, supported by oversold technical conditions (RSI: 44.09/38.00, Williams %R: -86.49) and strong pipeline catalysts (e.g., EMA approval for Olumiant, oral GLP-1 progress). The analyst argues that the proposed stop-loss at $950 (5.3% downside) is adequate given the growth trajectory and underpenetrated GLP-1 market.
  • Conservative Analyst: Technical indicators signal a downtrend, with price breaching all moving averages and high volatility (ATR: $34.55). The dynamic P/E of 91.43 is unsustainable, and historical data shows a 50% stop-loss trigger rate and -10.50% maximum adverse excursion (MAE), indicating high risk. The analyst contends that the $950 stop-loss is too tight for LLY’s volatility and recommends waiting for technical confirmation of a reversal before entering to prioritize capital protection.
  • Neutral Analyst: While fundamentals are strong, technical risks are real. A phased approach is advised: initial buy near $1,000, add positions if price drops to $950–$970, with a wider stop-loss at $920–$930 to account for volatility. This balances upside potential with risk management, acknowledging macro factors (e.g., FDA actions, competitive dynamics) that could impact performance.

Buy Eli Lilly and Company (LLY). The fundamental strength, oversold technicals, and historical precedents support this as a high-probability entry. The Conservative Analyst’s risks are managed through a disciplined stop-loss, and the Neutral Analyst’s phased approach is unnecessary given the clear oversold signal. Hold is not recommended—past data shows LLY rewards decisive action, not hesitation.

Trader plan

Execution plan

Refined Trader Plan

  • Action: Buy at current price (~$1,003.57), with stop-loss at $950 (5.3% risk).
  • Adjustments:
    • Consider a slightly wider stop at $943 (-6%) if volatility concerns persist, but $950 is adequate based on historical MAE.
    • Position sizing at 3-5% of portfolio aligns with ATR volatility.
  • Catalysts to Monitor: Q1 2026 earnings (April 2026), oral GLP-1 updates, and competitive moves by Novo Nordisk. Exit if fundamentals deteriorate (e.g., growth deceleration).
AI Risk Assessment Discussion
Round-by-round arguments
Round 1

Round 1 · Aggressive

  • Speaker argues Eli Lilly's weak technicals are overshadowed by its strong fundamentals, high growth, and market position, viewing the pullback as a high-reward entry opportunity.

Detail Preview

Look, I've seen the technical analysis showing LLY is in a short-term downtrend and trading below all major moving averages. But focusing solely on these bearish signals is exactly the kind of conservative thinking that causes investors to miss massive opportunities. This isn't some speculative biotech startup - we're talking about Eli Lilly, a company with 94.9% net income growth and 44.7% revenue growth! When you h…

Round 1 · Neutral

  • 作者指出，激进分析师忽略了Lilly股票看跌的技术指标，如均线下破和MACD动量
  • 保守分析师则低估了其强劲基本面，如高收入增长
  • 建议采取中性策略：在支撑位逢低分步建仓，设置更宽止损，而非完全看多或看空

Detail Preview

Let me break down both perspectives here, because honestly, both the aggressive and conservative analysts are leaning too hard into their biases without acknowledging the full picture. To the aggressive analyst: You're absolutely right about Lilly's fundamentals—94% net income growth and dominant positioning in the GLP-1 market are incredible. But you're brushing off the technical reality here. The stock isn't just "…

Round 1 · Conservative

  • A speaker cautions against buying Eli Lilly stock, citing technical indicators showing a downtrend, high P/E valuations, and concerns that the proposed stop-loss is too tight for the stock's volatility. A smaller position or waiting for a b

Detail Preview

Let me address this from a conservative risk management perspective. While I acknowledge Eli Lilly's strong fundamentals, I must strongly caution against this "Buy" recommendation at current levels. The risk-reward ratio simply doesn't justify the proposed position sizing. First, let's examine the technical picture. The stock is trading below ALL major moving averages - this isn't just a "pullback," it's a confirmed…

Round 2

Round 2 · Aggressive

  • 演讲者反驳保守与中立分析师观点，认为当前股价回调是机会而非风险
  • 强调公司强劲基本面增长、低估估值、积极催化剂及合理风控，主张积极策略以捕捉潜在高回报

Detail Preview

Let me address my cautious colleagues directly because I think both of you are missing the forest for the trees here. Conservative analyst—you're focusing entirely on technical indicators while ignoring the explosive fundamental story. Yes, the stock is trading below moving averages—that's exactly what creates the opportunity! This 9.4% pullback from highs isn't a breakdown—it's a gift. When a company delivers 94.9%…

Round 2 · Neutral

  • 该发言分析了Lilly股票的两种对立观点：激进派看好其强劲基本面和高增长，保守派关注技术面风险和估值过高
  • 建议采取分步建仓策略，在1000美元附近初始买入，下跌至950-970美元追加，设置宽松止损于920-930美元，并强调需同时考虑宏观环境因素

Detail Preview

我理解两位分析师的观点，但认为他们各自的立场都有些极端。让我来剖析一下： 激进分析师说这次回调是机会而非风险，这确实有一定道理。从基本面看，Lilly的增长数据确实惊人 - 94.9%的净利润增长和44.7%的收入增长不是随便哪个公司都能做到的。他们强大的产品管线，特别是GLP-1领域的领导地位，以及最近的监管批准都支撑着长期看涨的故事。 但这里的问题是，他们完全忽略了技术面的警告信号。股价跌破所有主要移动平均线不是小事 - 这显示了持续的下行压力。动态市盈率91倍即使对于高增长公司来说也是极高的，这确实让股票容易受到任何增长放缓的影响。 另一方面，保守分析师过于关注技术面风险而忽略了基本面实力。建议等待技术确认再入场听起来谨慎，但可能意味着错过最佳入场点。当技术指标确认反转时，股价可能已经从低点反弹了5-10%，这对于追求超额回报的投资者来说是个问题。 我认为更平衡的做法是：承认当前确实存在技术面弱势，但不过度反应。考虑到基本…

Round 2 · Conservative

  • 该发言对积极和中性分析师提出技术性质疑，指出股价跌破所有移动平均线呈下跌趋势，动态市盈率过高，波动性大，历史数据显示高风险
  • 建议等待技术确认反转后再考虑入场，强调资本保护和耐心

Detail Preview

Let me address both the aggressive and neutral analysts directly. First, to the aggressive analyst: You're calling this pullback an opportunity, but you're ignoring the critical technical breakdown we're seeing. The stock is trading below ALL major moving averages – that's not just a "pullback," that's a confirmed downtrend pattern. When MA 60 MA 20 MA 10 MA 5 and price is below all of them, that's textbook bearish s…

Assessment complete